1. Home
  2. ALX vs URGN Comparison

ALX vs URGN Comparison

Compare ALX & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alexander's Inc.

ALX

Alexander's Inc.

HOLD

Current Price

$250.06

Market Cap

1.3B

Sector

Real Estate

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$25.73

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALX
URGN
Founded
1928
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
1994
2016

Fundamental Metrics

Financial Performance
Metric
ALX
URGN
Price
$250.06
$25.73
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$29.29
AVG Volume (30 Days)
27.7K
704.1K
Earning Date
05-04-2026
05-11-2026
Dividend Yield
7.24%
N/A
EPS Growth
N/A
N/A
EPS
5.50
N/A
Revenue
$213,183,000.00
$1,128,000.00
Revenue This Year
N/A
$129.09
Revenue Next Year
N/A
$70.96
P/E Ratio
$45.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$198.57
$3.42
52 Week High
$260.84
$30.00

Technical Indicators

Market Signals
Indicator
ALX
URGN
Relative Strength Index (RSI) 57.53 75.81
Support Level $228.61 $18.55
Resistance Level $248.67 $30.00
Average True Range (ATR) 6.22 1.42
MACD 1.26 0.74
Stochastic Oscillator 81.83 82.27

Price Performance

Historical Comparison
ALX
URGN

About ALX Alexander's Inc.

Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: